Raymond E. Cabillot Sells 7,674 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 7,674 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $45.00, for a total value of $345,330.00. Following the sale, the director now directly owns 310,978 shares of the company’s stock, valued at $13,994,010. This trade represents a 2.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Pro-Dex Stock Down 2.6 %

PDEX opened at $46.53 on Thursday. Pro-Dex, Inc. has a fifty-two week low of $16.83 and a fifty-two week high of $59.60. The business has a 50-day moving average of $39.93 and a 200-day moving average of $37.82. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The company has a market capitalization of $151.73 million, a PE ratio of 23.15 and a beta of 0.68.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Equities research analysts forecast that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PDEX. Ritholtz Wealth Management bought a new position in Pro-Dex in the 4th quarter worth approximately $572,000. FMR LLC increased its position in Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after buying an additional 1,028 shares during the period. Geode Capital Management LLC increased its position in Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after buying an additional 2,296 shares during the period. JPMorgan Chase & Co. increased its position in Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after buying an additional 529 shares during the period. Finally, Bard Associates Inc. increased its position in Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 2,031 shares during the period. 15.28% of the stock is owned by institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.